New drug for rare eye disease begins first human tests
NCT ID NCT07417566
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests the safety of an oral drug called DC6001 in 76 healthy adults. Researchers will give single or multiple doses to see how the body handles the drug and if it causes side effects. This study does not involve people with Stargardt disease and is not designed to test if the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DC6001 tablet
- What this could lead to
- If safe and well-tolerated, this could pave the way for future studies testing DC6001 as a potential treatment for Stargardt disease.
- What could go wrong
- This is a very early Phase 1 trial in healthy volunteers, not patients. It only tests safety and drug levels, not whether the drug works for the disease. Many drugs fail at this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STARGARDT DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Tongren Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can stem cells restore vision in stargardt disease? a First-in-Human trial aims to find out
- Could stem cells restore sight in damaged eyes?
- New study tracks stargardt disease to pave way for future treatments
- New eye camera could unlock secrets of inherited blindness
- New cell therapy aims to slow vision loss in retinal disease
- Thousands join fight against blindness by sharing their stories